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In this study, we investigated the antipsychotic-like effect of methanolic extract of
Mitragyna speciosa leaf (MMS) using in vivo and ex vivo studies. In vivo studies
comprised of apomorphine-induced climbing behavior, haloperidol-induced catalepsy,
and ketamine-induced social withdrawal tests in mice whereas the ex vivo study was
conducted utilizing isolated rat vas deferens preparation. Acute oral administration of
MMS (50–500 mg/kg) showed an inverted bell-shaped dose-response in apomorphine-
induced cage climbing behavior in mice. The effective inhibitory doses of MMS (75
and 100 mg/kg, p.o.) obtained from the apomorphine study was further tested on
haloperidol (subcataleptic dose; 0.1 mg/kg, i.p.)-induced catalepsy in the mouse
bar test. MMS (75 and 100 mg/kg, p.o.) significantly potentiated the haloperidol-
induced catalepsy in mice. Interestingly, MMS at the same effective doses (75 and
100 mg/kg, p.o.) significantly facilitated the social interaction in ketamine-induced
social withdrawal mice. Furthermore, MMS inhibited the dopamine-induced contractile
response dose-dependently in the isolated rat vas deferens preparations. In conclusion,
this investigation provides first evidence that MMS exhibits antipsychotic-like activity with
potential to alleviate positive as well as negative symptoms of psychosis in mice. This
study also suggests the antidopaminergic activity of MMS that could be responsible for
alleviating positive symptoms of psychosis.
Keywords: apomorphine, bar test, climbing behavior, haloperidol, ketamine, Mitragyna speciosa, social
withdrawal, vas deferens
INTRODUCTION
Psychosis is a devastating mental illness with a high economic burden for many countries. The
molecular mechanisms involved in the pathogenesis of psychosis has been extensively studied
and reported in the literature (Saugstad, 2008). In an attempt to reduce the severity of this
disease worldwide, many pharmacological treatment options have been constantly developed.
Currently available antipsychotics are mainly classified into two categories: typical antipsychotics
(e.g., chlorpromazine, haloperidol etc.) and atypical antipsychotics (e.g., clozapine, risperidone
etc.). The former class of drugs are effective to treat only the positive symptoms such as delusion,
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hallucination, and stereotypy behavior by blocking dopamine
D2 receptors of the mesolimbic pathway in the brain whereas
atypical antipsychotics are able to treat both positive as well
as negative symptoms such as withdrawal from social contacts,
anhedonia, and flattening of emotional responses by blocking
D2, 5HT2A, and adrenergic (α2) receptors (Horacek et al., 2006).
Both classes of antipsychotics possess classical adverse effects
profile. For example, extrapyramidal motor disturbances such as
acute dystonia and tardive dyskinesia are commonly observed
with typical antipsychotics whereas weight gain, ventricular
arrhythmias, agranulocytosis are some of the common adverse
effects of atypical antipsychotics (Howard et al., 2007). Therefore,
a search for an alternative antipsychotics to effectively treat both
positive and negative symptoms with lesser or no adverse effects
is a continuous process in the research world.
Many researchers have opted to natural resources, mostly
herbal remedies in order to develop an efficient therapy (Carlini,
2003). Mitragyna speciosa Korth. (M. Speciosa), commonly
known as ketum or kratom, is an ever green tree from coffee
family (Rubiaceae) mostly found in Thailand and northern
Malaysia. Traditionally, M. speciosa leaf has been used to relieve
pain, cough, diarrhea, hypertension and it has also been used
as a substitute drug to treat opioids addicts (Reanmongkol
et al., 2001; Chee et al., 2008). Moreover, M. speciosa leaf has
been reported for antipyretic, antidiarrheal, analgesic, and local
anesthetic activities (Burkill, 1996). Interestingly, M. speciosa
has been reported for central nervous system stimulant as
well as depressant activities at different doses (Chittrakarn
et al., 2010). Mitragynine is the main bioactive compound
present in the leaf of M. speciosa responsible for various CNS
activities such as alleviation of ethanol withdrawal symptoms and
antidepressant activity in mice (Kumarnsit et al., 2007; Idayu
et al., 2011). The pharmacological effects of mitragynine have
mainly been explained for its interaction with dopaminergic,
adrenergic, and serotonergic receptors (Matsumoto et al., 1996,
1997; Yamamoto et al., 1999; Reanmongkol et al., 2001; Horie
et al., 2005; Boyer et al., 2008; Shamima et al., 2012). Moreover,
in vitro radioligand-binding assays revealed that mitragynine
possess inhibitory effect on selected receptors: adrenergic (α2)
[61.9%], dopamine (D2) [54.2%], serotonin [5HT2C (58.8%)
and 5HT7 (64.4%)] receptors (Boyer et al., 2008). It has also
been observed that the long-term consumption of M. speciosa
leaf darkened the skin although the user remained indoors
(Norakanphadung, 1966). The claim for the darker skin of
habitual user of M. speciosa leaf is intriguing and suggested
that it could be due to combination of psychoactive properties
and molecular structure of mitragynine (Jansen and Prast,
1988b). It has been reported that the activation of the dopamine
type 2 (D2) receptors in the rat pituitary gland attenuated
the release of α-melanocyte stimulating-like peptides (Kebabian
et al., 1984). Therefore, it has been postulated that mitragynine
darkened the skin by inhibiting dopamine D2 receptors whereby
increasing melanocyte-stimulating substances. Jansen and Prast
(1988a) proposed if mitragynine proved to be a D2 receptor
antagonist, it could be effectively utilized to treat psychosis.
However, based on our thorough literature search, to date
there was no report on antipsychotic activity of M. speciosa
leaf. Therefore, the present study was aimed to investigate the
antipsychotic-like activity of MMS using in vivo and ex vivo
studies.
MATERIALS AND METHODS
Drugs and Chemicals
In vivo Studies
Methanolic extract of Mitragyna speciosa and clozapine
(Clozarem R©, Remedica-Cyprus) solution was prepared as
suspension using 1% w/v sodium carboxymethyl cellulose
(CMC) solution and administrated orally (p.o.). Haloperidol
solution [Manace R©, Duopharma (M) SDN. BHD, Malaysia]
and ketamine hydrochloride solution (Chemistry Department,
Ministry of Health, Malaysia) were prepared with normal
saline. Apomorphine hydrochloride (Sigma–Aldrich, USA) was
dissolved in normal saline containing sodium metabisulphite
(0.125% w/v). All drug solutions were prepared fresh and
administrated in a constant volume of 1 ml/100g body weight
of the animal. The different doses of MMS used in the present
in vivo study was chosen based on the reported lethal and
therapeutic doses of MMS. LD50 of MMS was found at 4.90 g/kg
in mice (Reanmongkol et al., 2001) and its CNS activities
were reported at 50–1000 mg/kg (Reanmongkol et al., 2001;
Sabetghadam et al., 2010; Senik et al., 2012).
Ex vivo Studies
Dopamine hydrochloride and dimethyl sulfoxide (DMSO)
(Sigma–Aldrich, USA) were used. Chemicals used to prepare
Krebs physiological salt solution were obtained from Sigma–
Aldrich, USA. All drug solutions were prepared fresh in double
distilled water. The stock solution of different concentrations of
MMS was prepared using DMSO (0.1%v/v).
Plant Collection and Identification
Fresh leaf of M. speciosa Korth was collected from Alor
Setar Kedah, Malaysia. The leaf was authenticated by Rimba
Ilmu, Institute of Biological Sciences, University of Malaya and
a voucher specimen (KLU 47980) was deposited for future
reference.
Preparation of Methanolic Extract of M. speciosa
(MMS)
Fresh M. speciosa leaf (10 kg) was cleaned under running tap
water to remove adhering material and dirt, shade dried for
2 weeks and crushed into coarse powder. Two kilograms of the
powdered leaf was successively macerated with 10 L of methanol
(isocratic HPLC grade, Scharlau, Spain) for 20 h and then
proceeded the sonication using water-bath sonicator at room
temperature (25◦C) for 4 h. The methanol extractive was filtered
using a filter paper. Methanol solvent from the extractive was
removed by evaporation using rotary evaporator. Approximately,
230 g of dried crude methanolic extract of M. speciosa (MMS)
was obtained and it was then transferred into an amber air tight
container and stored at 4◦C until further use.
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LC-MS/MS Analysis and Mitragynine
Quantification
The liquid chromatography (LC) analysis was performed using
a Shimadzu UFLC system, fitted with a PDA detector (diode
array detector, DAD), a column heater-cooler, a vacuum degasser,
a quaternary pump, and an autosampler. Separation was done
using an XBridge C18 column (2.1 mm × 50 mm, 2.5 µm)
and maintained at 40◦C. The compound elution was carried out
using a linear gradient solvent system consisting of solvent A
(0.1% formic acid) and solvent (B) (acetonitrile with 0.1% formic
acid) as follows: 0–100% B over 7 min, followed by isocratic
elution with 100% solvent (B) from 7 to 15 min, then returned
to 10% from 13 min at a flow rate of 0.5 ml/min. The compound
separation was monitored with both UV detector at 254 nm and a
mass spectrometry detector which operated in positive ionization
mode with spectra acquired over a mass range of 50–1000 m/z.
A concentration of 5 mg/mL MMS and standard (mitragynine
obtained from ChromaDex) stock was prepared in methanol
and filtered through a 0.22 nylon filter prior the analysis. The
standard calibration graph was plotted with peak area against the
serially diluted mitragynine. The amount of mitragynine in the
MMS extract was then quantified accordingly using the linearity
equation of standard curve.
Animals
Swiss albino male mice (body weight, 25–30 g) and Sprague-
Dawley (SD) male rats (body weight, 250–350 g), obtained from
the Animal Experimental Unit, University of Malaya were used
in this study. The animals were housed in a group of four
in individually ventilated cages. They were fed with standard
laboratory food pellet and allowed access to water ad libitum
and maintained under the standard animal laboratory conditions;
12 h light: 12 h dark cycle (lights off at 19.00 h), 45–55%
relative humidity and temperature of 22 ± 1◦C. The animals
were allowed to acclimatize to laboratory conditions for at
least 1 week prior to experiments. All experimental procedures
used in this study adhered to the guidelines of the National
Research Council of the National Academies of the USA (“Guide
for the Care and Use of Laboratory Animals”)(Garber et al.,
2011) and were assessed and approved by the Institutional
Animal Care and Use Committee, University of Malaya [Ethics
No.FARMAKO/18/03/2014/PV(R)].
In vivo Studies
Effect of MMS on Apomorphine-Induced Climbing
Behavior in Mice
The animals were segregated into eight groups (n = 8 in each
group). Group I served as a vehicle-control group, received
1% w/v CMC solution (1 ml/100 g, p.o.); Group II was given
apomorphine (5 mg/kg, i.p.). Group III, IV, V, VI, VII, and
VIII animals were administered with MMS at different doses
of 50, 75, 100, 125, 250, and 500 mg/kg, p.o., respectively,
60 min prior to apomorphine injection. The naïve mice were
first let to acclimatize to the observation cylindrical metal cage
(18 cm × 19 cm) consist of horizontal (4.5 cm apart) and
vertical (1 cm apart) metal bars (2 mm) with upper lid for
15 min prior to the experiment. After 15 min acclimatization
of the animals in the cylindrical metal cage, they received an
intraperitoneal injection of apomorphine (5 mg/kg). Immediately
after apomorphine injection, the mice were individually placed
at the base of corresponding cylindrical cages. The climbing
behavior was assessed every 5 min for 30 min and scored using
the following rating scale: 4 = four paws on the wall (Climbing),
2 = two paws on the wall of the cage, 0 = four paws on the floor
as described in our earlier publication (Pandy et al., 2012). The
total score of 6 time points during 30 min study (every 5 min)
was calculated and represent as a climbing index. The maximum
possible climbing index was 24. Additionally, the duration of
climbing by the animal on the wall and lid of metal cages was
recorded and represent as a climbing time for 30 min.
Effect of MMS on Catalepsy Produced with
Subcataleptic Dose of Haloperidol
This test was conducted using a standard bar test as described
elsewhere (Sanberg, 1980). Forepaws of naive mice were placed
over a horizontal metal bar (diameter: 3 mm), upraised 4.5 cm
from the floor and the time entail to remove the forepaws from
the bar was recorded as the duration of catalepsy in seconds. The
effective doses of MMS (75 and 100 mg/kg, p.o.) obtained from
the apomorphine study or 1% w/v CMC (10 ml/kg, p.o.) was
administered 30 min prior to a subcataleptic dose of haloperidol
(0.1 mg/kg, i.p.) injection. The subcataleptic dose of haloperidol
was chosen in order to differentiate potentiation or reversal
effect of drugs on haloperidol-induced catalepsy based on earlier
published report (Pandi et al., 2007). The cataleptic behavior
of each mouse was recorded at 0 and 60 min after haloperidol
injection.
Effect of MMS on Ketamine-Induced Social
Withdrawal in Mice
The social interaction test was carried out using the method
previously described elsewhere (Qiao et al., 2001). Briefly, mice
were housed in eight animals per cage (familiar group) and
acclimatized to a 12 h reversed light cycle (lights on at 20:00 h)
for 2 weeks prior to the experiments. Transparent acrylic box
35 (L) × 20 (W) × 18 (H) cm without a lid was used as social
interaction apparatus and the experiments were conducted with
a red bulb (15 W) placed above the test box. The mice were
introduced to a habituation session prior to the test, whereby each
mouse was isolated in the test box for 10 min. During test day,
mice were allocated in pairs composed of animal matched for
body weight and pertaining to unfamiliar groups (different home
cages) that received the same drug treatment. The bodyweights
of the paired mice were matched within 1–2 g of variance.
Group of mice (N = 16) were randomly assigned to treatment
groups receiving saline, clozapine (1 mg/kg, p.o.) or MMS (50–
500 mg/kg, p.o.) 1 h prior to the test session and ketamine
(10 mg/kg, i.p.) was administrated 30 min before the behavioral
test. The behavior of each of these pairs was recorded on a camera
located above the test box for 10 min for later analysis. All the
behavioral observation such as the latency to the first contact and
the time spent in social interaction (crawling under or over the
partner, genital investigation, following, sniffing and grooming
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the partner) of each pairs were analyzed by the trained observer
who was blind to the treatment group. Passive contact such as
lying or sitting with bodies in contact was not considered as a part
of social interaction. The test box was wiped clean with alcohol
between each trial to remove the evidence of the presences of
other mice. Additionally, the locomotor activity was measured
using the method described elsewhere (Satow et al., 2009). The
locomotion of each mice was accessed as the number of lines
(marked on the floor of the box) crossed by the mice during the
test.
Ex vivo Studies
Effect of MMS on Dopamine-Induced Contractility in
the Isolated Rat Vas Deferens Preparation
Vas Deferens Tissue Preparation
The SD rats were sacrificed by CO2 inhalation and a pair of vas
deferens were immediately isolated and carefully cleaned from
connective tissues and blood vessels. The epididymal portions of
vas deferens were cut into the length of 1 cm and were vertically
mounted in 10 mL organ chambers containing 5 mL of Krebs
physiological salt solution (KPSS in mM: KCI 4.7, KH2PO4 1.2,
NaCl 119, NAHCO3 25, MgSO4.7H2O 1.2, CaCI2.2H2O 2.5,
and glucose 11.7) at 37◦C, gassed with 5% CO2 and 95% O2 to
achieve a desired pH of 7.3–7.4. The tissue was stretched to 0.5 g
tension and allowed to equilibrate for 60 min before initiation of
experimental protocols. The isometric tension (g) was measured
using force transducer connected to the PowerLab recording
system (AD Instruments, Australia). During this stabilization
period, the bath solution was replaced every 15 min. Following
equilibration, the contractile responses of the tissue were tested
for viability by the addition of 10% KC1 (high K+) for 4 min
every 10 min until two consecutive equal contractions were
obtained.
Dopamine-Induced Contractile Response on Isolated
Rat Vas Deferens
To plot the dose-response curve (DRC) of dopamine (DA), a
non-cumulative doses of DA (0.4–102.4 µg/mL) were tested on
the rat vas deferens preparations as described in our earlier
publication (Pandy et al., 2014). From the DRC of DA, a
submaximal dose of DA (25.6 µg/mL) was chosen for further
investigation. The effect of various concentrations of MMS
(1–100 µg/mL, 5 min incubation) or DMSO 0.001% (final
concentration) on the contraction of the chosen submaximal
dose of DA was investigated. The inhibitory effect of MMS
on the contraction induced by the submaximal dose of DA
was compared with vehicle control (DMSO). The percentage
contractile response of the submaximal dose of DA was calculated
with respect to high K+ contractile response. Furthermore, the
nature of antagonism was examined in the presences of DMSO
(0.001%v/v), MMS (1, 5, 10, and 20 µg/ml) or a D2 receptor
antagonist, haloperidol (1.6, 3.2, 6.4, and 12.8 µg/ml) on the log
DRCs of DA.
Statistical Analysis
All experimental results were analyzed using one-way analysis of
variance (ANOVA) followed by Dunnett’s multiple comparison
tests. As for the ex vivo studies, the concentrations indicated
in the text or in the figures represent the final tissue-bath
concentration of the drug. The responses were recorded as
mean ± standard error of mean (SEM) and “n” indicates
number of rats used for each set of data. The data were
analyzed using Graph Pad Prism version 5.0 statistical
software. A level of p < 0.05 was considered as statistically
significant.
RESULTS
LC-MS/MS Analysis and Mitragynine
Quantification
In order to quantify the amount of mitragynine in the MMS
extract, a fast and sensitive LC-MS method was developed
and used. In Figure 1, mitragynine (m/z 399.2) was eluted at
3.1 min. The calibration linearity of mitragynine was reported as
Y = 0.1811∗X + 20.03. The concentration of mitragynine was
found to be 4.44 µg /ml of MMS extract, or equally to 4.4% w/w.
In vivo Studies
Effect of MMS on Apomorphine-Induced Climbing
Behavior in Mice
Methanolic extract of Mitragyna speciosa (50–500 mg/kg, p.o.)
showed significant inverted bell-shaped inhibitory response
on apomorphine-induced climbing time [F(7,56) = 4.829;
p < 0.0003] and climbing behavior [F(7,56)= 6.408; p < 0.0001].
Dunnett’s post hoc analysis revealed that MMS at 75 and
100 mg/kg, p.o., significantly attenuated the apomorphine-
induced cage climbing time and climbing behavior as shown in
Figures 2A–C.
Effect of MMS on Catalepsy Produced with
Subcataleptic Dose of Haloperidol in Bar Test
The effective doses of MMS (75 and 100 mg/kg, p.o.) obtained
from the apomorphine-induced climbing behavior was tested
on subcataleptic dose of haloperidol (0.1 mg/kg, i.p.)-induced
catalepsy in mice. As shown in Figure 3, MMS at doses 75 and
100 mg/kg, p.o., significantly potentiated the haloperidol-induced
catalepsy time [F(3,28)= 19.51; p < 0.0001] in mice.
Effect of MMS on Ketamine-Induced Social
Withdrawal in Mice
Ketamine (10 mg/kg, i.p.) significantly induced social withdrawal
by attenuating social interaction time between two naive mice
when compared with saline treated group (Figure 4). MMS
(75 and 100 mg/kg, p.o.) significantly reversed the ketamine-
induced social withdrawal in mice [F(8,63)= 16.17; p < 0.0001].
Additionally, it has been observed that ketamine (10 mg/kg,
i.p.) significantly (p < 0.01) increased the locomotor activity
when compared with saline control group. Dunnett’s post
hoc analysis revealed that MMS at 75 and 100 mg/kg, p.o.,
also significantly (p < 0.05) reversed ketamine-induced hyper
motility in mice [F(8,135) = 3.149; p < 0.0027] as shown in
Figures 4A,B.
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FIGURE 1 | The LC-MS chromatogram of the target compound, mitragynine, with molecular mass m/z (+) 399.2 was detected at 3.1 min.
Ex vivo Studies
Effect of MMS on Dopamine-Induced Contractility of
Isolated Rat Vas Deferens Preparations
Dopamine exhibited dose-dependent contractile response in
epididymal segments of the isolated vas deferens preparation
(Figure 5). A submaximal dose (25.6 µg/mL) of dopamine
was chosen from the DRC and it was subsequently used for
further studies. MMS at different concentrations (1–100 µg/mL)
for 5 min incubation significantly depressed the contractile
responses of submaximal dose of dopamine (25.6 µg/mL) in
dose-dependent manner as shown in Figure 6. In order to
evaluate the nature of antagonism by MMS on dopaminergic
system, few selected doses of MMS (1, 5, 10, and 20 µg/mL)
or haloperidol (1.6, 3.2, 6.4, and 12.8 µg/mL) were tested
on DRC of dopamine. MMS and haloperidol, a D2 receptor
antagonist dose-dependently shifted the DRC of dopamine to
rightward with significant reduction in the maximal response
(Figures 7A,B). However, the pEC50 was not significantly altered
in both treatment groups (Tables 1 and 2).
DISCUSSION
Psychosis animal models are developed based on the
neurochemical theory of schizophrenia, primarily involving
neurotransmitters such as dopamine and glutamate and it
has been used to screen new chemical entities (NCEs) for
potential antipsychotic-like effect (Lipska and Weinberger,
2000). Apomorphine-induced cage climbing behavior in mice
is a widely used animal model to evaluate the antipsychotic
potential of NCEs (Szechtman, 1986). Apomorphine is known
to activate both D1 and D2 dopamine receptors to exhibit these
animal behavior (Seeman, 1980; Stoof and Kebabian, 1984).
Most of the antipsychotic drugs available in the market are
known to suppress the cage climbing behavior by inhibiting
the dopaminergic D2 receptors (Szechtman, 1986; Davis et al.,
1991; Baldessarini and Tarazi, 2001). This study demonstrated
that the acute oral treatment of MMS (50, 75, 100, 125, 250,
and 500 mg/kg) showed an inverted bell-shaped dose-response
relationship in the mouse cage climbing behavior. MMS at doses
(75 and 100 mg/kg) significantly decreased the climbing behavior
and climbing time in mice. The inhibitory effect of MMS against
apomorphine-induced cage climbing behavior suggests the
antipsychotic-like effect of MMS mediated by its interaction with
the dopaminergic system.
Nucleus accumbens and corpus striatum are commonly
suggested as major brain regions associated with antipsychotics-
induced catalepsy, which seems as a result of blockade associated
with dopaminergic neurotransmission. Besides, a drug which
increases the dopaminergic neurotransmission suppresses the
neuroleptic-induced catalepsy (Rang et al., 2003). A non-selective
dopamine D2 blocker, for example, haloperidol induced catalepsy
by inhibiting the dopamine D2 receptors in the striatum. The
ability of the test compounds to potentiate or inhibit the
haloperidol-induced catalepsy in rodents is an indicative of a
reduction or augmentation of dopaminergic neurotransmission,
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FIGURE 2 | Effect of methanolic extract of Mitragyna speciosa (MMS) (50–500 mg/kg, p.o.) on cage climbing behavior and cage climbing time
induced by apomorphine (APO 5 mg/kg, i.p.) in mice. (A) Total time spent on the wall of the cage. (B) The cumulative climbing scores were measured for
30 min after apomorphine administration. (C) The climbing behavior was scored at 5 min interval after apomorphine treatment. Each point represents the
mean ± SEM from the scores obtained from eight animals. Statistical significance: ###p < 0.001 compared with the saline control group; ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 compared with the vehicle control (VEH) group.
respectively. In this study, MMS (75 and 100 mg/kg) significantly
potentiated catalepsy time induced by subcateleptic dose of
haloperidol in mice which implies the antidopaminergic activity
of MMS. Interestingly, all tested doses of MMS (50–500 mg/kg,
p.o.) per se did not affect the mice behavior in bar test (Data
not shown). These results suggest that the effective doses
of MMS per se possessed antipsychotic-like activity without
causing extrapyramidal symptoms like catalepsy. Importantly,
the antagonism of dopamine D2 receptors by the most clinically
proven antipsychotic drugs often associated with alleviation of
positive symptoms of psychosis such as stereotyped behavior,
hallucinations and delusions etc (Gardner et al., 2005). Therefore,
it is postulated that MMS could alleviate positive symptoms
of psychosis without causing extrapyramidal side effects like
catatonia.
To further demonstrate the potential of MMS as an
antipsychotic drug for the negative symptoms of psychosis,
MMS was tested on ketamine-induced social withdrawal in
mice. Ketamine-induced social withdrawal in mice is an
established animal model mimicking the negative symptoms
of schizophrenic patients (Ellenbroek and Cools, 2000). The
antagonism of NMDA receptors by ketamine on the GABAergic
neurons leads to decrease the release of GABA, results in the
excessive striatal glutamate release, which stimulates the excess
release of dopamine, and 5-HT and this causes hyperactivation
of D2 and 5-HT2 receptors, respectively, produce symptoms
of hyperactivity (positive symptom) and social interaction
deficits (negative symptom) (Homayoun and Moghaddam, 2007;
Chatterjee et al., 2012; Uribe et al., 2013). Impressively, in
this study, MMS (50, 75, 100, 125, 250, and 500 mg/kg,
p.o.) showed a bell-shaped reversal response on ketamine-
induced social withdrawal in mice. Moreover, MMS at doses
75 and 100 mg/kg significantly reversed the social deficit
induced by ketamine. According to (Corbett et al., 1993), typical
antipsychotic drugs deficit the social interaction behavior in
rodents whereas atypical antipsychotic drugs tend to facilitate
the social interaction behavior. In the present study, a well-
known atypical antipsychotic drug, clozapine (1 mg/kg, p.o.)
significantly increased the social interaction time in the
ketamine-induced social withdrawal animals. This finding is in
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FIGURE 3 | Effect of MMS (75 and 100 mg/kg, p.o.) on subcataleptic
dose of haloperidol (HAL)-induced catalepsy in bar test. Values are
expressed as mean ± SEM. Statistical significance: ∗∗p < 0.01, ∗∗∗p < 0.001
compared with the vehicle control (VEH) group; when not indicated the
differences were not significant.
agreement with previously reported data (Satow et al., 2009) in
which acute treatment of clozapine was found to elevate the
social interaction time in ketamine-induced social withdrawal
mice. However, haloperidol, a typical antipsychotic drug was
unable to reverse NMDA receptor agonists (PCP, and MK801)-
induced social withdrawal in mice (Qiao et al., 2001; De Moura
Linck et al., 2008). One of the main mechanisms involved
to alleviate the negative symptoms of psychosis are mediated
through inhibition of 5HT2A receptors (Cepeda and Levine, 2006;
Stone et al., 2007). Interestingly, mitragynine the main bioactive
constituent of M. speciosa has been reported to possess the 5HT2A
antagonistic-like effect in 5-Methoxy-N, N-dimethyltryptamine-
induced head-twitch response in mice (Matsumoto et al., 1997).
Therefore the reversal of ketamine-induced hyperactivity and
social withdrawal defects observed with MMS might be mediated
through the inhibition of dopamine D2 receptors and serotonin
5HT2A receptors.
To further elucidate the dopaminergic mediated actions of
MMS, ex vivo studies using isolated rat vas deferens preparations
were carried out. Dopamine D2 receptors are predominantly
existed in rat vas deferens and dopamine produce contractile
response in rat vas deferens (Boadle-Biber and Roth, 1975).
From the data obtained, MMS (1–100 µg/ml) dose-dependently
inhibited the contractility evoked by a submaximal concentration
of dopamine (25.6 µg/mL). Moreover, the log-dose response
curve of dopamine was dose-dependently shifted rightward with
a depression of maxima in presence of MMS (1–20 µg/ml)
as shown in Figure 7A and Table 1. The reference drug,
haloperidol also showed similar rightward shift with depression
of maxima (Figure 7B; Table 2). However, pEC50 values were not
significantly altered at different doses of both MMS (1–20 µg/ml)
and haloperidol (1.6–12.8 µg/ml) (Tables 1 and 2). These results
demonstrate the non-competitive blocking effect of MMS on
dopaminergic receptors. To demonstrate the potency of MMS
FIGURE 4 | Effect of MMS (50–500 mg/kg, p.o.) or clozapine (CLZ;
1 mg/kg, p.o.) on ketamine-induced (A) social interaction time and (B)
number of line crossings. Statistical significance: ###p < 0.001, ##p < 0.01
compared with the saline control group; ∗∗p < 0.01, ∗p < 0.05 compared
with the vehicle control (VEH) group.
FIGURE 5 | Log dose response curve of dopamine (DA) expressed as
% contraction over 80 mM High K (n = 4).
with respect to haloperidol, pEC50 values were compared with
haloperidol. pEC50 for the MMS (5 µg/mL) is 1.34 ± 0.07 while
for haloperidol (6.4 µg/mL) is 1.42 ± 0.04, which indicates
Frontiers in Pharmacology | www.frontiersin.org 7 December 2016 | Volume 7 | Article 464
fphar-07-00464 December 3, 2016 Time: 13:59 # 8
Vijeepallam et al. Mitragyna speciosa Exhibits Antipsychotic-Like Effect
FIGURE 6 | Effect of MMS (1–100 µg/ml) on DA (25.6 µg/ml)-induced
contraction expressed as % contraction over 80 mM High K. ∗p < 0.05
compared with DMSO; n = 4.
FIGURE 7 | Log dose response curves of dopamine in the absence and
presence of (A) MMS and (B) haloperidol (HAL) expressed as % contraction
over 80 mM High K. ∗p < 0.05, ∗∗∗p < 0.001 when compared with DMSO;
n = 4.
that MMS has a similar potency as haloperidol, a dopamine
D2 blocker. These results confirm the antidopaminergic effect
of MMS which is responsible for the antipsychotic-like effect of
MMS observed in in vivo studies.
TABLE 1 | Effect of MMS (1–20 µg/mL) on the pEC50 and % maximal
contraction (% Emax) of dopamine-induced contractions of isolated rat
vas deferens.
Treatment pEC50 % Emax
DMSO (0.001%) 1.23 ± 0.07 27.13 ± 3.66
MMS (1 µg /mL) 1.23 ± 0.07 24.68 ± 3.58
MMS (5 µg /mL) 1.34 ± 0.07 19.02 ± 2.66
MMS (10 µg /mL) 1.01 ± 0.08 4.30 ± 0.60∗∗∗
MMS (20 µg /mL) 1.40 ± 0.05 1.40 ± 0.19∗∗∗
∗∗∗p < 0.001 when compared with DMSO (0.001%).
TABLE 2 | Effect of haloperidol (1.6–12.8 µg/mL) on the pEC50 and %
maximal contraction (% Emax) of dopamine-induced contractions of
isolated rat vas deferens.
Treatment pEC50 % Emax
DMSO (0.001%) 1.31 ± 0.04 21.94 ± 2.93
HAL (1.6 µg/mL) 1.32 ± 0.04 19.87 ± 2.71
HAL (3.2 (µg/mL) 1.37 ± 0.03 18.17 ± 2.43
HAL (6.4 µg/mL) 1.42 ± 0.04 14.15 ± 1.88
HAL (12.8 µg/mL) 1.53 ± 0.07 10.32 ± 1.30∗
∗p < 0.05 when compared with DMSO (0.001%).
Dopaminergic (D2)-receptors are the main pharmacological
target for treatment of schizophrenia (Missale et al., 1998;
Beaulieu and Gainetdinov, 2011). It has been proposed
that the positive symptoms are mediated through hyper-
activation of mesolimbic dopaminergic D2 receptors and
the negative symptoms by hypo-activation of mesocortical
dopaminergic D1 receptors (Toda and Abi-Dargham, 2007).
Similarly, glutamatergic NMDA receptors blockade produces
both positive and negative psychotic symptoms. For example,
dizocilpine, ketamine, and phencyclidine (NMDA antagonists)
produce both positive and negative psychotic symptoms in
humans (Millan, 2005). Negative psychotic symptoms are also
improved by the blockade of 5HT2A receptors. Activation of
serotonergic 5-HT2A receptors presents in presynaptic nerve
terminals of dopaminergic and glutamatergic neurons inhibit
the release of dopamine and glutamate, respectively. Atypical
antipsychotics such as clozapine, olanzapine, and risperidone
block 5HT2A receptors thereby enhancing the release of
dopamine and glutamate in mesocortical circuit and improve
the negative symptoms of schizophrenia (Rang et al., 2016).
Moreover, clozapine and olanzapine also act as 5-HT2C inverse
agonists. 5-HT2C receptor stimulation can also inhibit cortical
dopamine release (Katzung and Trevor, 2015). Mitragynine has
been shown to inhibit 5-HT2C receptors in in vitro radioligand
binding assay (Boyer et al., 2008). In present study, MMS at
75 and 100 mg/kg significantly alleviated both positive and
negative psychotic-like symptoms in mice. The present results
do not clarify the exact neuronal mechanism involved in the
antipsychotic-like effect of MMS at 75 and 100 mg/kg. However,
it has been postulated that MMS (75 and 100 mg/kg, p.o.) could
block dopamine D2 receptors and serotonin 5-HT2A/5-HT2C
receptors thereby improve both positive and negative symptoms
of psychosis in mice.
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Methanolic extract of Mitragyna speciosa at higher doses
(>125 mg/kg) did not alleviate both positive and negative
symptoms of psychosis in mice. The clinical efficacy of
all approved typical and atypical antipsychotic drugs are
mainly mediated by blocking post-synaptic D2 receptors in
the brain (Seeman, 2010). Interestingly, D2 receptors also
act as autoreceptors in the presynaptic nerve terminals of
the dopaminergic neurons and inhibit the synthesis and
release of dopamine (Bello et al., 2011; Anzalone et al.,
2012). Thus, there is a possibility that MMS at higher
doses (125–500 mg/kg) could block pre-synaptic D2 receptors
thereby stimulate the release of dopamine and lose its
antipsychotic effect. Further studies in this direction are
warranted to confirm the actual mechanism of action of
MMS.
The phytochemical analysis results revealed the presence
of mitragynine in MMS by its major peak at a retention
time, 3.1 min. 4.44 µg /ml or equally to 4.4% w/w of
mitragynine was quantified in MMS which was consistent with
earlier published reports (Jansen and Prast, 1988a; Ponglux
et al., 1994; Chittrakarn et al., 2010). Mitragynine, being the
maximum dominant active alkaloid present in M. speciosa
is responsible for the diverse pharmacological activities of
this plant (Azizi et al., 2010). Interestingly, mitragynine
significantly inhibited the dopamine (D2) and serotonin (5-HT2)
receptors in a radioligand-binding assay (Boyer et al., 2008).
Therefore, it is hypothesized that antipsychotic-like effect of
MMS could be mediated by its main bioactive constituent,
mitragynine.
In summary, this study results demonstrated that
MMS (75 and 100 mg/kg, p.o.) significantly reversed the
apomorphine-induced cage climbing behavior (positive
symptoms), attenuated ketamine-induced hyperactivity
(positive symptoms), improved ketamine-induced social
withdrawal deficits (negative symptoms) and potentiated
the haloperidol induced catalepsy in mice, respectively.
Further, the antidopaminergic effect of MMS was mediated
through the non-competitive antagonism of D2 receptors in
ex vivo study using isolated rat vas deferens preparation.
Overall, this study highlighted antipsychotic-like effect
of MMS that could be mediated through blockade of
dopaminergic (D2) and serotonergic (5-HT2A/5-HT2C)
receptors.
CONCLUSION
Methanolic extract of Mitragyna speciosa is found to be effective
in alleviating positive as well as negative symptoms of psychosis
in mouse models and it could be mainly mediated through
inhibition of D2 and 5-HT2 receptors. Therefore, MMS could
be utilized for the development of novel antipsychotic drug to
treat both positive and negative symptoms of psychosis. However,
further mechanistic studies to demonstrate antipsychotic-like
effect of MMS are warranted. The studies in this direction are
currently underway in our laboratory.
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